GlobeNewswire

Aducanumab is good; next generation Alzheimer’s disease therapies will be better

Share

New data for aducanumab strengthens potential for Alzheimer’s therapy in near term, fuels next-generation therapies with more selective binding for toxic species of amyloid beta

TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, commends Biogen for its trailblazing efforts to advance aducanumab. Data released today at CTAD (Clinical Trials on Alzheimer’s Disease conference) strengthen aducanumab’s potential to become the first disease-modifying therapy for Alzheimer’s disease. The data clearly underscore the need for next-generation drug candidates that offer more precise binding to the misfolded beta amyloid oligomer (AßO), the toxic species of the amyloid beta protein and root cause of Alzheimer’s disease.

“Today’s presentation reflects yet another landmark step toward the approval of a disease-modifying therapy for Alzheimer’s disease, which, we must remember, is currently the only top-ten cause of death without treatment,” said ProMIS Neurosciences Chief Medical Officer James Kupiec, MD. “The aducanumab data is indeed good news, but the compound has limitations. History frequently shows that first-generation therapies for the most challenging diseases often have major efficacy or safety limitations.  In heart disease, cancer and HIV, first-generation efforts often paved the way for better, safer medicines, and the same will be true for Alzheimer’s disease by more precisely targeting only the toxic species of amyloid beta and thereby avoiding the dose-limiting side effects associated with unwanted off-target binding. We will get there.  Biomarkers will help us get there faster, but aducanumab is a tremendous first step.”

New data for aducanumab affirm a statistically significant reduction in cognitive and functional decline for participants in the EMERGE trial. As clinical benefit depends on the amount of antibody that can reach the pathogenic species of amyloid beta, data continue to show that aducanumab demonstrates limited selectivity for AßOs: off-target binding to amyloid plaque was associated with adverse and dose-limiting ARIA-E (brain swelling) in 35% of trial participants despite attempts to minimize it by titrating drug dosing.

PMN310 is a next generation drug candidate that offers more precise selectivity for AßOs, which is expected to provide greater clinical benefit and safety based upon current preclinical data. Created using a novel drug discovery and development platform that can uniquely and precisely target the toxic forms of otherwise normal proteins, PMN310 demonstrates a high degree of binding to toxic oligomers without binding to non-toxic forms of amyloid beta. Data also demonstrate PMN310’s greater therapeutic potency versus other Aß-directed antibodies. For more information about PMN310, please visit www.promisneurosciences.com.

To learn more about the search for therapies for Alzheimer’s, Parkinson’s and other neurodegenerative diseases, listen to Saving Minds, at iTunes or Spotify.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Resolutions at the Annual General Meeting in Eolus Vind AB on January 25th, 202025.1.2020 17:45:00 CETPress release

Hässleholm, Sweden, January 25th, 2020. In accordance with the Board of Directors’ proposal, the Annual General Meeting (“AGM”) resolved to declare a dividend of SEK 1.50 per share for the financial year 2018/2019, and the record date for the payment of dividends was set to Tuesday, January 28th, 2020. The Board members and the CEO were discharged from liability. Sigrun Hjelmqvist, Hans Johansson, Jan Johansson, Hans Linnarson, Bodil Rosvall Jönsson and Hans-Göran Stennert were re-elected as members of the Board of Directors and Hans-Göran Stennert was re-elected as chairman of the Board. Accounting firm PricewaterhouseCoopers AB was re-elected as the company’s auditor, with authorized public accountant Eva Carlsvi as auditor in charge. It was decided that fees to the Board of Directors shall amount to SEK 1,250,000 in total, whereby the fee to the chairman shall amount to SEK 375,000 and the fees for each of the other Board members that are not employed by the company shall amount to

Beslut vid årsstämman i Eolus Vind AB den 25 januari 202025.1.2020 17:45:00 CETPressemelding

Hässleholm den 25 januari 2020. I enlighet med styrelsens förslag fastställde årsstämman utdelningen för räkenskapsåret 2018/2019 till 1,50 kronor per aktie med tisdagen den 28 januari 2020 som avstämningsdag. Bolagets styrelseledamöter och VD beviljades ansvarsfrihet. Sigrun Hjelmqvist, Hans Johansson, Jan Johansson, Hans Linnarson, Bodil Rosvall Jönsson samt Hans-Göran Stennert omvaldes till styrelseledamöter och Hans-Göran Stennert omvaldes som styrelsens ordförande. Registrerade revisionsbolaget PricewaterhouseCoopers AB omvaldes till revisor med auktoriserade revisorn Eva Carlsvi som huvudansvarig revisor. Arvode till styrelsen beslutades utgå med totalt 1 250 000 kronor, varav 375 000 kronor till ordföranden och 175 000 kronor vardera till övriga styrelseledamöter som inte är anställda i bolaget. Vidare beslutade stämman att arvode till revisorn ska utgå enligt avtal. I enlighet med förslag från valberedningen fastställde stämman instruktioner för utseende av valberedningen och v

Gold Lion Closes Acquisition of Cuteye Group of Properties24.1.2020 22:05:00 CETPress release

VANCOUVER, British Columbia, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Gold Lion Resources Inc. (“Gold Lion” or the “Company”) (CSE: GL) (FWB: 2BC) is pleased to announce that it has closed its acquisition of the Cuteye Group of Properties from a private British Columbia numbered company (“Numberco”) (see the Company’s January 13, 2020 news release previously announcing the transaction). Under the transaction, Gold Lion issued an aggregate of 6,000,000 Gold Lion common shares to the shareholders of Numberco. No finder’s fees were paid in connection with the transaction. Gold Lion also announces the appointment of Mr. Dan Dente as a Director of the Company. Mr. Dente brings over 20 years’ experience within the financial services industry. About Gold Lion Resources Inc. Gold Lion Resources Inc. is a mineral exploration company, actively involved in the exploration of the Cuteye Group of Properties, as well as the Fairview Copper-Silver-Zinc Property. The Cuteye Group of Properties includes the M

Notice of fourth quarter 2019 results and conference call24.1.2020 18:05:00 CETPress release

Notice of fourth quarter 2019 results and conference call Luxembourg, January 24th, 2020 – Millicom will announce its fourth quarter results for the period ending December 31st, 2019, on February 25th, 2020 at approximately 12:00 (Stockholm) / 11:00 (London) / 6:00 (Miami) via a press release. The company will host a conference call for the global financial community on February 25th, 2020 at 14:00 (Stockholm) / 13:00 (London) / 08:00 (Miami). The conference call will be webcast at www.millicom.com Dial-in information: Please dial in 5-10 minutes before the scheduled start time to register your attendance. Dial-in numbers for the call are as follows: Sweden: +46 (0) 8506 92180 Luxembourg: +352 2786 0515 UK: +44 (0) 2071 928000 US: +1 631 5107 495 The access code is: 2348098 Replay information: A replay of the call will be available for 7 days from February 25th, 2020 at: UK: +44 (0) 3333 009785 US: +1 (917) 677-7532 Replay passcode is: 2348098 For further information, please contact Pr

Arion Bank: Share buyback program expanded in Iceland and Sweden24.1.2020 17:15:00 CETPress release

Reference is made to the Bank’s announcement concerning the Bank’s share buyback program in Iceland and Sweden published on 31 October 2019 and the change to the program published on 9 January 2020. The Board of Directors of Arion Bank has approved a revised buyback program on the basis of the authorization provided at the Bank's AGM on 20 March 2019 and the approval given by the Financial Supervisory Authority/Central Bank of Iceland on 23 January 2020. The revised share buyback program authorizes the Bank to buy a maximum of 100,000,000 shares/SDRs, corresponding to 5.5% of issued shares in the Bank, for up to ISK 8 billion at market value. The revised program represents an increase of up to 41 million shares/SDRs, corresponding to 2.3% of issued shares in the Bank, for up to ISK 3.5 billion at market value, in the Bank’s authorization to buy back shares. When the share buyback program was issued on 31 October 2019 the Bank was authorized to buy up to 59 million shares/SDRs for up to

DFDS: INVITATION TO CONFERENCE CALL FOR DFDS´ REPORT FOR Q4 201924.1.2020 16:40:00 CETPress release

Investor news Company announcement no 1. DFDS expects to publish the report for Q4 2019 on 6 February 2020 at around 08:00 AM CET. Torben Carlsen, CEO, and Karina Deacon, CFO, will present the report on a live conference call. The presentation in English will be followed by a Q&A session. Investors, analysts and other interested parties are invited to take part. Date: 6 February 2020 Time: 10:00 AM CET Telephone DK +45 35445577 US +1 631 913 1422 UK +44 33 33000804 List of international numbers: https://event.sharefile.com/share/view/s451667d1ca54c838 Access code: 66655871# If you wish to take part in the audio conference, please dial up at least five minutes before the conference begins. It will start on time, and participants will be asked to register name and company name beforehand. The conference will be broadcast live on https://www.dfds.com/en/about and published there for future reference. Contact Søren Brøndholt Nielsen, IR +45 33 42 33 59 Attachment UK_OMX_no_01_Conference_ca